Korey A Kennelty1, Nels J Engblom2, Barry L Carter3, Liz Hollingworth4, Barcey T Levy5, Rachel J Finkelstein2, Christopher P Parker2, Yinghui Xu6, Kayla L Jackson4, Jeffrey D Dawson7, Kathryn K Dorsey2. 1. Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, United States; Department of Family Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, United States. Electronic address: korey-kennelty@uiowa.edu. 2. Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, United States. 3. Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, United States; Department of Family Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, United States. 4. Department of Educational Policy and Leadership Studies, College of Education, University of Iowa, United States. 5. Department of Family Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, United States; Department of Epidemiology, College of Public Health, University of Iowa, United States. 6. Department of Family Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, United States. 7. Department of Biostatistics, College of Public Health, University of Iowa, United States.
Abstract
BACKGROUND: Medical clinics are increasingly hiring clinical pharmacists to improve management of cardiovascular disease (CVD). However, the limited number of clinical pharmacists employed in a clinic may not impact the large number of complex patients needing the services. We have developed a remote telehealth service provided by clinical pharmacists to complement CVD services provided by on-site clinical pharmacists and aid sites without a clinical pharmacist. This cardiovascular risk service (CVRS) has been studied in two NIH-funded trials, however, we identified barriers to optimal intervention implementation. The purpose of this study is to examine how to implement the CVRS into medical offices and see if the intervention will be sustained. METHODS: This is a 5-year, pragmatic, cluster-randomized clinical trial in 13 primary care clinics across the US. We randomized clinics to receive CVRS or usual care and will enroll 325 patient subjects and 288 key stakeholder subjects. We have obtained access to the electronic medical records (EMRs) of all study clinics to recruit subjects and provide the pharmacist intervention. The intervention is staggered so that after 12 months, the usual care sites will receive the intervention for 12 months. Follow-up will be accomplished though medical record abstraction at baseline, 12 months, 24 months, and 36 months. CONCLUSIONS: This study will enroll subjects through 2021 and results will be available in 2024. This study will provide unique information on how the CVRS provided by remote clinical pharmacists can be effectively implemented in medical offices, many of which already employ on-site clinical pharmacists. CLINICAL TRIAL REGISTRATION INFORMATION: NCT03660631: http://clinicaltrials.gov/ct2/show/NCT03660631.
BACKGROUND: Medical clinics are increasingly hiring clinical pharmacists to improve management of cardiovascular disease (CVD). However, the limited number of clinical pharmacists employed in a clinic may not impact the large number of complex patients needing the services. We have developed a remote telehealth service provided by clinical pharmacists to complement CVD services provided by on-site clinical pharmacists and aid sites without a clinical pharmacist. This cardiovascular risk service (CVRS) has been studied in two NIH-funded trials, however, we identified barriers to optimal intervention implementation. The purpose of this study is to examine how to implement the CVRS into medical offices and see if the intervention will be sustained. METHODS: This is a 5-year, pragmatic, cluster-randomized clinical trial in 13 primary care clinics across the US. We randomized clinics to receive CVRS or usual care and will enroll 325 patient subjects and 288 key stakeholder subjects. We have obtained access to the electronic medical records (EMRs) of all study clinics to recruit subjects and provide the pharmacist intervention. The intervention is staggered so that after 12 months, the usual care sites will receive the intervention for 12 months. Follow-up will be accomplished though medical record abstraction at baseline, 12 months, 24 months, and 36 months. CONCLUSIONS: This study will enroll subjects through 2021 and results will be available in 2024. This study will provide unique information on how the CVRS provided by remote clinical pharmacists can be effectively implemented in medical offices, many of which already employ on-site clinical pharmacists. CLINICAL TRIAL REGISTRATION INFORMATION: NCT03660631: http://clinicaltrials.gov/ct2/show/NCT03660631.
Authors: E H Wagner; A Z LaCroix; L Grothaus; S G Leveille; J A Hecht; K Artz; K Odle; D M Buchner Journal: Am J Public Health Date: 1994-11 Impact factor: 9.308
Authors: Barry L Carter; William R Doucette; Carrie L Franciscus; Gail Ardery; Karen M Kluesner; Elizabeth A Chrischilles Journal: Pharmacotherapy Date: 2010-03 Impact factor: 4.705
Authors: Susan A Oliveria; Pablo Lapuerta; Bruce D McCarthy; Gilbert J L'Italien; Dan R Berlowitz; Steven M Asch Journal: Arch Intern Med Date: 2002-02-25
Authors: David E Demik; Mark W Vander Weg; Emily S Lundt; Christopher S Coffey; Gail Ardery; Barry L Carter Journal: Res Social Adm Pharm Date: 2013-03-16
Authors: Linnea A Polgreen; Jayoung Han; Barry L Carter; Gail P Ardery; Christopher S Coffey; Elizabeth A Chrischilles; Paul A James Journal: Hypertension Date: 2015-11-02 Impact factor: 10.190